PLK1 and breast cancer: Finally, we recommended our proposed BC-causing five upregulated (COL11A1, COL10A1, CD24, PLK1, UBE2C) and three down-regulated (PDK4, CD36, ACACB) HubGs-guided top-ranked six ligands/molecules (Suramin, Rifaximin, Telmisartan, Tukysa Tucatinib, Lynparza Olaparib, TG.02) as the candidate drug molecules by molecular docking analysis.